Scoring systems for the assessment of individual risk of HCC development during long term treatment with NAs
| Score | Patients evaluated | Included parameters | Cut off (points) | Performance |
| CU-HCC | Asian patients: 1005 in training and 424 in validation cohort | Age, albumin, bilirubin, HBV DNA, cirrhosis | 5 | 97% NPV over 10 years |
| GAG-HCC | Asian patients (n=820) | Age, sex, HBV DNA, cirrhosis | 101 | 99% NPV over 10 years |
| REACH-B | Asian non-cirrhotic patients: 3584 in trainings and 1505 validation cohort | Age, sex, ALT, HBV DNA, HBeAg status | 8 | 98% NPV over 10 years |
| PAGE-B | European patients: 1325 in training and 490 in validation cohort | Age, sex, platelets | <6 | 100% NPV over up to 5 years |
Author Profile
Dr. D.Zeqiraj medical doctor at QKUK- Pristina, department of Infectious disease.